Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**Long intergenic non-protein coding RNA 1813 (LINC01813)** is a non-coding RNA gene, classified as a long intergenic non-coding RNA (lincRNA)[3]. LincRNAs are autonomously transcribed RNA molecules longer than 200 nucleotides that do not overlap annotated coding genes[1][5]. These RNAs are part of the broader long non-coding RNA (lncRNA) family and are implicated in various gene regulation processes such as chromatin remodeling, modulation of transcription, and RNA stability[1][5]. While many lincRNAs have demonstrated regulatory functions and context-dependent biological roles, the specific function and disease relevance of LINC01813 has not yet been established in the literature. As such, LINC01813 is not currently considered a therapeutic target, nor are there known drug interactions, biomarker uses, or safety concerns associated with this particular lincRNA[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1813 (LINC01813).